[1] |
Bray F, Ferlay J, Soerjomataram I,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018, 68(6):394-424.
|
[2] |
Zheng RS, Sun KX, Zhang SW,et al. Report of cancer epidemiology in China, 2015[J]. Zhonghua Zhong Liu Za Zhi,2019, 41(1):19-28.
|
[3] |
Scimeca M, Urbano N, Bonfiglio R,et al. Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology[J]. Biochim Biophys Acta Rev Cancer,2019, 1872(1):138-148.
|
[4] |
Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target[J]. Mol Aspects Med,2018, 62:75-88.
|
[5] |
Jitariu AA, Raica M, Cimpean AM,et al. The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast[J]. Crit Rev Oncol Hematol,2018, 131:46-52.
|
[6] |
Ross R, Glomset J, Kariya B,et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro[J]. Proc Natl Acad Sci U S A,1974, 71(4):1207-1210.
|
[7] |
Kazlauskas A. PDGFs and their receptors[J]. Gene,2017, 614:1-7.
|
[8] |
Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms[J]. Cytokine Growth Factor Rev,2004, 15(4):197-204.
|
[9] |
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine[J]. Genes Dev,2008, 22(10):1276-1312.
|
[10] |
Sil S, Periyasamy P, Thangaraj A,et al. PDGF/PDGFR axis in the neural systems[J]. Mol Aspects Med,2018, 62:63-74.
|
[11] |
Bessonnard S, Vandormael-Pournin S, Coqueran S,et al. PDGF signaling in primitive endoderm cell survival is mediated by PI3K-mTOR through p53-independent mechanism[J]. Stem Cells,2019, 37(7):888-898.
|
[12] |
Tannenberg P, Chang YT, Muhl L,et al.Extracellular retention of PDGF-B directs vascular remodeling in mouse hypoxia-induced pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol,2018, 314(4):L593-L605.
|
[13] |
Su M, Yue Z, Wang H,et al. Ufmylationis activated in vascular remodeling and lipopolysaccharide-induced endothelial cell injury[J]. DNA Cell Biol,2018, 37(5):426-431.
|
[14] |
Dadrich M, Nicolay NH, Flechsig P,et al. Combined inhibition of TGF beta and PDGF signaling attenuates radiation-induced pulmonary fibrosis[J]. Oncoimmunology,2015, 5(5):e1123366.
|
[15] |
Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis[J]. Mol Aspects Med,2018, 62:44-62.
|
[16] |
Wang Y, Appiah-Kubi K, Wu M,et al. The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer[J]. Growth Factors,2016, 34(1/2):64-71.
|
[17] |
Östman A. PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment[J]. Adv Drug Deliv Rev,2017, 121:117-123.
|
[18] |
Appiah-Kubi K, Lan T, Wang Y,et al. Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies[J]. Crit Rev Oncol Hematol,2017, 109:20-34.
|
[19] |
Sharma VK, Singh A, Srivastava SK,et al. Increased expression of platelet-derived growth factor associated protein-1 is associated with PDGF-B mediated glioma progression[J]. Int J Biochem Cell Biol,2016, 78:194-205.
|
[20] |
Manzat Saplacan RM, Balacescu L, Gherman C,et al. Therole of PDGFs and PDGFRs in colorectal cancer[J]. Mediators Inflamm,2017, 2017:4708076.
|
[21] |
Qian H, Appiah-Kubi K, Wang Y,et al. The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol,2018, 127:15-28.
|
[22] |
Bartoschek M, Pietras K. PDGF family function and prognostic value in tumor biology[J]. Biochem Biophys Res Commun,2018, 503(2):984-990.
|
[23] |
王媚媚,秦晓红,米立志. 血小板衍生生长因子受体结构与功能的研究[J]. 中国科学:生命科学,2019, 49(6):683-697.
|
[24] |
Slattery ML, John EM, Stern MC,et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study[J]. Breast Cancer Res Treat,2013, 140(3):587-601.
|
[25] |
Bronzert DA, Bates SE, Sheridan JP,et al. Transforming growth factor-beta induces platelet-derived growth factor (PDGF) messenger RNA and PDGF secretion while inhibiting growth in normal human mammary epithelial cells[J]. Mol Endocrinol,1990, 4(7):981-989.
|
[26] |
Coltrera MD, Wang J, Porter PL,et al. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma[J]. Cancer Res,1995, 55(12):2703-2708.
|
[27] |
Feakins RM, Wells CA, Young KA,et al. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast[J]. Hum Pathol,2000, 31(10):1214-1222.
|
[28] |
Sistigu A, Di Modugno F, Manic G,et al. Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting[J]. Cytokine Growth Factor Rev,2017, 36:67-77.
|
[29] |
Frings O, Augsten M, Tobin NP,et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling[J]. Am J Pathol,2013, 182(6):2037-2047.
|
[30] |
Jechlinger M, Sommer A, Moriggl R,et al. Autocrine PDGFR signaling promotes mammary cancer metastasis[J]. J Clin Invest,2006, 116(6):1561-1570.
|
[31] |
Kadivar A, Kamalidehghan B, Akbari Javar H,et al. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-beta, PDGF-BB, c-Kit and SCF genes[J]. Drug Des Devel Ther,2017, 11:469-481.
|
[32] |
Zhang Y, Zhao Y, Li L,et al. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells[J]. Biochem Biophys Res Commun,2013, 434(2):305-310.
|
[33] |
Yokoyama Y, Mori S, Hamada Y,et al. Platelet-derived growth factor regulates breast cancer progression via beta-catenin expression[J]. Pathobiology,2011, 78(5):253-260.
|
[34] |
Primac I, Maquoi E, Blacher S,et al. Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression[J]. J Clin Invest,2019,129(11):4609-4628.
|
[35] |
Zhang Y, He W, Zhang S. Seeking forcorrelative genes and signaling pathways with bone metastasis from breast cancer by integrated analysis[J]. Front Oncol,2019, 9:138.
|
[36] |
Ribatti D. Endogenous inhibitors of angiogenesis: a historical review[J]. Leuk Res,2009, 33(5):638-644.
|
[37] |
Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med,1971, 285(21):1182-1186.
|
[38] |
Zuazo-Gaztelu I, Casanovas O. Unraveling therole of angiogenesis in cancer ecosystems[J]. Front Oncol,2018, 8:248.
|
[39] |
Jin S, Yang C, Huang J,et al. Conditioned medium derived from FGF-2-modified GMSCs enhances migration and angiogenesis of human umbilical vein endothelial cells[J]. Stem Cell Res Ther,2020, 11(1):68.
|
[40] |
Gianni-Barrera R, Butschkau A, Uccelli A,et al. PDGF-BB regulates splitting angiogenesis in skeletal muscle by limiting VEGF-induced endothelial proliferation[J]. Angiogenesis,2018, 21(4):883-900.
|
[41] |
Ding X, Xi W, Ji J,et al. HGF derived from cancer-associated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling[J]. Oncol Rep,2018, 40(2):1185-1195.
|
[42] |
Thijssen VL, Paulis YW, Nowak-Sliwinska P,et al. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth[J]. J Pathol,2018, 246(4):447-458.
|
[43] |
Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment[J]. Am J Pathol,2003,162(4):1083-1093.
|
[44] |
Gialeli C, Nikitovic D, Kletsas D,et al. PDGF/PDGFR signaling and targeting in cancer growth and progression: Focus on tumor microenvironment and cancer-associated fibroblasts[J]. Curr Pharm Des,2014, 20(17):2843-2848.
|
[45] |
Pinto MP, Dye WW, Jacobsen BM,et al. Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling[J]. BMC Cancer,2014, 14:735.
|
[46] |
Czekierdowska S, Stachowicz N, Chrós'ciel M,et al. Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B[J]. Ginekol Pol,2017, 88(3):120-128.
|
[47] |
Vrekoussis T, Stathopoulos EN, Kafousi M,et al. Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta[J]. Oncol Rep,2007, 17(5):1115-1119.
|
[48] |
Wagner KD, Du S, Martin L,et al. Vascular PPAR beta/delta promotes tumor angiogenesis and progression[J]. Cells,2019, 8(12):1623.
|
[49] |
Hsu YL, Yen MC, Chang WA,et al. CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB[J]. Breast Cancer Res,2019, 21(1):23.
|
[50] |
Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy[J]. Pharmaceuticals (Basel),2010, 3(3):572-599.
|
[51] |
Lev DC, Kim SJ, Onn A,et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice[J]. Clin Cancer Res,2005, 11(1):306-314.
|
[52] |
Roskoski R Jr. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders[J]. Pharmacol Res,2018, 129:65-83.
|
[53] |
Waller CF. Imatinibmesylate[J]. Recent Results Cancer Res,2018, 212:1-27.
|
[54] |
Cristofanilli M, Morandi P, Krishnamurthy S,et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations[J]. Ann Oncol,2008, 19(10):1713-1719.
|
[55] |
Yang L, Li N, Xue Z,et al. Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer[J]. Cell Death Differ,2020, 27(7):2066-2080.
|
[56] |
Watanabe T, Koyama N. Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma[J]. Nihon Yakurigaku Zasshi,2019, 153(5):242-248.
|
[57] |
Yam C, Murthy RK, Rauch GM,et al. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-beta[J]. Invest New Drugs,2018, 36(6):1103-1109.
|
[58] |
Paulsson J, Ryden L, Strell C,et al. High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer[J]. J Pathol Clin Res,2016, 3(1):38-43.
|
[59] |
Zhang X, Blaskovich MA, Forinash KD,et al. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours[J]. Br J Cancer,2014, 111(5):894-902.
|
[60] |
Kaplan CD, Kruger JA, Zhou H,et al. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma[J]. Vaccine,2006, 24(47/48):6994-7002.
|
[61] |
Wang JC, Li GY, Wang B,et al. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation[J]. J Exp Clin Cancer Res,2019, 38(1):235.
|
[62] |
Oliveira C, Granja S, Neves NM,et al. Fucoidan from fucus vesiculosus inhibits new blood vessel formation and breast tumor growth in vivo[J]. Carbohydr Polym,2019, 223:115 034.
|
[63] |
Meng YQ, Zhou Y, Li QW,et al. Synthesis of oleanolic acid analogues targeting PDGF receptor inhibitors and their antitumor biological activities[J]. J Asian Nat Prod Res,2021, 23(2):150-162.
|